Researchers at Carnegie Mellon University’s School of Computer Science, the University of Pittsburgh School of Medicine, and the University of Washington have unveiled a previously under-explored dimension of Alzheimer’s disease, potentially unlocking new pathways for therapeutic intervention. Their seminal study, published in the prestigious journal Science, demonstrates that the intricate three-dimensional organization of the genome within specific brain cells is significantly altered in individuals afflicted with Alzheimer’s. This groundbreaking discovery links these architectural shifts in the genome to profound changes in gene activity and the overall organization of brain tissue, moving beyond the traditional focus on amyloid plaques and tau tangles.
A New Frontier in Alzheimer’s Research
For decades, the scientific community has primarily concentrated on the accumulation of amyloid-beta plaques and tau tangles as the defining hallmarks of Alzheimer’s disease. These protein aggregates are undeniably central to the neurodegenerative process. However, this latest research, spearheaded by Jian Ma, the Ray and Stephanie Lane Professor of Computational Biology at Carnegie Mellon, introduces a critical new layer of understanding. "Alzheimer’s disease cannot be understood one layer at a time," stated Professor Ma. "The genome’s 3D structure is a fundamental regulatory layer that helps to connect DNA sequence to gene activity. By integrating genome folding, cell state, and tissue context, we can move beyond cataloging disease-associated changes toward understanding how they fit together and which mechanisms to test next."
The human genome, a complex blueprint of life, is not merely a linear string of DNA. Instead, it is meticulously folded and organized into a sophisticated three-dimensional architecture within the cell nucleus. This intricate folding is crucial for regulating gene expression, dictating which genes are accessible and active at any given time. Disruptions to this precise spatial arrangement can have cascading effects on cellular function, and in the context of neurodegenerative diseases, these disruptions may contribute to the pathological processes underlying Alzheimer’s.
The Technological Symphony Behind the Discovery
To construct this unprecedentedly detailed picture of Alzheimer’s-affected brain cells, the interdisciplinary team employed a powerful combination of cutting-edge technologies. They leveraged single-cell technology, which allows for the analysis of individual cells, providing a granular view of cellular heterogeneity. This was integrated with spatial mapping of brain tissue, a technique that preserves the anatomical context of gene activity, showing where specific molecular events occur within the intricate network of the brain. Crucially, a newly developed deep learning model, named Hicformer, was instrumental in deciphering the complex relationships between genome folding and gene activity.
The study focused on postmortem samples from the prefrontal cortex, a brain region critical for cognitive functions such as decision-making, planning, and personality. These tissue samples were sourced from individuals who had participated in long-term dementia studies and had subsequently donated their brains for research. This ensured a robust and well-characterized cohort for analysis, allowing for a direct comparison between brains affected by Alzheimer’s disease and those of healthy controls.
Illuminating the Molecular Landscape: Beyond Amyloid and Tau
Hansruedi Mathys, an assistant professor of neurobiology at the University of Pittsburgh School of Medicine, who directed the Pitt arm of the study, emphasized the significance of these findings. "Our study represents a major advance in understanding what goes wrong in Alzheimer’s disease," he remarked. "We know the classic hallmarks of Alzheimer’s disease – accumulation of amyloid-beta plaques and tau tangles – but our results establish higher-order chromatin alterations as a component of the molecular pathology associated with the disease, which currently affects seven million Americans, a number that continues to grow."
Chromatin, the complex of DNA and proteins (primarily histones) that forms chromosomes, is the physical manifestation of the genome’s organization. The study’s findings suggest that alterations in chromatin structure, or "higher-order chromatin alterations," should now be considered a fundamental aspect of Alzheimer’s molecular pathology, alongside the well-established protein aggregates. This paradigm shift could open entirely new avenues for therapeutic development, targeting the very architecture of the genome.
The Role of Artificial Intelligence in Deciphering Genome Folding
A pivotal element in this research was the development and application of Hicformer, an artificial intelligence model designed to investigate the intricate influence of genome structure on cellular behavior. Hicformer ingeniously integrates DNA sequence information with broad patterns of genome folding and detailed maps of physical DNA-DNA contacts. This allows the AI to predict gene activity across diverse cell types with remarkable accuracy.
Xinyue Lu, a doctoral student in Computational Biology at Carnegie Mellon and a co-leader of the research, described Hicformer as a "computational test bed." This innovative system enables researchers to systematically explore how subtle or significant changes in genome folding might translate into altered gene activity. "Measuring gene activity and genome folding in the same cell allows us to directly connect chromosome structure with disease-related gene programs," explained Yang Zhang, a project scientist in Computational Biology and another co-leader of the study. "Across several kinds of brain cells, this paired view revealed a consistent signature of 3D genome reorganization in Alzheimer’s disease and helped us prioritize regulatory regions for future mechanistic and therapeutic investigation."
The GAGE-seq technique, employed in this study, was crucial in obtaining paired measurements of gene expression and 3D genome contacts within individual cells. When combined with spatial transcriptomic maps, which retain information about the location of gene activity within intact tissue, the researchers could establish a direct link between the physical organization of the genome and its regulatory mechanisms. This integrated approach allowed them to pinpoint where Alzheimer’s-related molecular and cellular changes manifested within the surrounding brain tissue.
Quantifiable Shifts in DNA Organization in Alzheimer’s
The researchers meticulously identified several consistent and significant differences in the genome architecture of brain cells from individuals with Alzheimer’s disease. Normally, large segments of the genome are organized into distinct regions, termed compartments, which are either transcriptionally active or inactive. In Alzheimer’s-affected cells, these boundaries appeared blurred, a phenomenon the researchers characterized as "increased compartment mingling." This suggests a loss of precise spatial segregation that normally dictates gene accessibility.
Furthermore, the study observed a reduction in interactions between DNA segments located in close proximity within the nucleus, while simultaneously noting an increase in contacts between DNA regions that are physically farther apart. This alteration in interaction patterns further contributes to the disorganization of the genome. Cells exhibiting greater compartment mingling tended to show lower overall levels of gene activity, indicating a potential link between structural disarray and functional impairment.
Another critical observation was the weakening of interactions between genes and their nearby regulatory elements – the DNA sequences that control gene expression. Conversely, interactions across intermediate genomic distances appeared to strengthen. These structural modifications were not isolated events; they were strongly associated with a decrease in the activity of genes crucial for neuronal function and synaptic plasticity, processes vital for learning and memory. Additionally, changes were noted in metabolic pathways and cellular stress responses, indicating a widespread cellular dysfunction. In microglia, the brain’s resident immune cells, the researchers identified links to senescence-related programs, suggesting that these crucial cells may be undergoing detrimental changes in Alzheimer’s.
Implications for Future Alzheimer’s Therapies
The comprehensive mapping of these molecular changes across intact brain tissue revealed a profound connection: the reorganization of the genome was not only associated with altered gene activity but also with observable differences in the spatial arrangement of brain cells. This suggests that changes in genome architecture may directly influence cellular behavior and tissue organization, contributing to the broader pathological cascade of Alzheimer’s disease.
These findings firmly establish three-dimensional genome organization as a critical, previously underappreciated, layer of Alzheimer’s disease biology. They provide a robust framework for future research aimed at dissecting which specific structural changes are drivers of disease progression and which affected regulatory regions could serve as potential targets for novel therapeutic interventions.
The implications for developing new treatments are substantial. Future investigations will likely focus on whether these observed structural alterations in the genome actively contribute to the onset and progression of Alzheimer’s. If so, interventions aimed at restoring normal genome architecture or targeting the regulatory elements affected by these changes could represent a paradigm shift in how Alzheimer’s is treated. For instance, understanding how compartment mingling affects specific gene networks could lead to the development of drugs that selectively re-establish compartmental boundaries or modulate the activity of genes that become aberrantly regulated due to these structural changes.
The research was generously supported by grants from the National Institutes of Health, underscoring the national priority placed on understanding and combating Alzheimer’s disease. The collaborative nature of this project, involving researchers from Carnegie Mellon University, the University of Pittsburgh, the University of Washington, the Broad Institute of MIT and Harvard, the University of California, Los Angeles, and the Rush Alzheimer’s Disease Center, highlights the power of inter-institutional cooperation in tackling complex scientific challenges. Among the contributing CMU authors were doctoral students Shahul Alam and Shike Wang, and postdoctoral research associate Junjie Tang. Pitt’s contributions included doctoral students Alexander K. Kunisky and Jude Baroudi, post-baccalaureate research fellows Sahar and Sahel Ghorbanikalateh, and visiting scholar Shihan Wang. This collective effort has significantly advanced our understanding of a devastating disease, offering a renewed sense of hope for millions affected by Alzheimer’s.
